Exagen：一家接近转折点的小型诊断公司 (NASDAQ:XGN)
· seekingalpha.com
Exagen (XGN) 买入评级：营收增长加速，平均售价 (ASP) 改善，并有望在 2027 年实现盈亏平衡。
Exagen (NASDAQ: XGN ) is becoming a very interesting diagnostics company as revenue growth accelerates, average selling prices are improving, and management mov...